Vast Therapeutics
  • Home
  • About
    • Company Overview
    • Our Team
    • Scientific Advisory Board
    • Careers
  • Technology
    • Nitric Oxide
    • Need for Antibiotic Alternatives
    • Broad Spectrum Efficacy
  • Applications
    • Cystic Fibrosis
    • NTM Lung Disease
    • Other Targets
  • Media
  • Investors

Media

​New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’

10/4/2017

 
​New Nitric Oxide Treatment Eradicates Emerging ‘Superbugs’
More than 2 Million Americans Infected Each Year, 23,000 Die from Antibiotic-Resistant Bacteria

DURHAM, NC (October 4, 2017) – Novoclem Therapeutics, a biotech company focused on advancing nitric oxide therapies for the treatment of respiratory diseases, today announced that data from an in vitro study with BIOC51, a nitric oxide-releasing biopolymer being developed for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis patients, will be presented at the 2017 ID Week conference in San Diego, California this week.

Novoclem’s study, conducted by researchers at Southern Research Institute, demonstrated broad spectrum in vitro eradication of multi drug resistant bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae and Pseudomonas aeruginosa. These bacteria have been identified by the Centers of Disease and Control Prevention (CDC) as rapidly spreading and severe public threats in infectious diseases due to the limited availability of new antibiotic treatments.

“Superbugs are a significant barrier to effectively treating the most severe infections. In fact, both the CDC and the World Health Organization have identified antibiotic-resistant bacteria as one of the most serious health threats we face,” said Dr. Mark Schoenfisch, Professor of Chemistry at the University of North Carolina at Chapel Hill, co-inventor of the nitric oxide-releasing biopolymer, and Novoclem’s Chief Scientific Officer. “The broad spectrum antibacterial action of nitric oxide and its short half-life in blood avoid systemic side effects, which make this technology highly attractive for treating drug-resistant bacteria.”

About the Presentations

Session: 167. Preclinical Study with New Antibiotics and Antifungals
Session Date: Friday, October 6, 2017
Session Time: 12:30 p.m. – 2 p.m.
Session Location: Poster Hall
Presentation Title: Nitric Oxide-Releasing Chitosan for the Treatment of Multi-Drug Resistant Superbugs
Presentation/Poster Number: 1535

About Novoclem Therapeutics, Inc.

Novoclem Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, is an innovative, preclinical-stage pharmaceutical company focused on helping people who suffer from severe respiratory diseases to breathe better and live life more fully. It is initially focused on developing a nitric oxide based treatment for people living with cystic fibrosis and infected with Pseudomonas aeruginosa. The company anticipates submitting an Investigational New Drug application and initiating First in Human clinical trials in 2018. More info available at vasttherapeutics.com.

About KNOW Bio LLC

KNOW Bio, LLC, is a life science company committed to improving and extending people’s lives by advancing the development and commercialization of its drug and device pipeline through wholly or majority owned subsidiary companies. Each of the subsidiaries is focused on specific therapeutic applications where nitric oxide can provide meaningful health benefit.

Forward-looking Statements

​Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: risks associated with the drug development process; reliance on key personnel; the early stage of our business; competition; and other risks described in other Company press releases and presentations. KNOW Bio and Novoclem Therapeutics assumes no obligation and does not intend to update these forward-looking statements, except as required by law.


Comments are closed.


    Archives

    September 2020
    October 2019
    May 2019
    January 2019
    December 2018
    May 2018
    February 2018
    January 2018
    November 2017
    October 2017
    July 2017
    April 2017
    January 2017


    ​Categories

    All
    Anthrax
    BIOC11
    BIOC51
    Biotech Showcase
    CED
    CFF
    Conference
    COVID-19
    Cystic Fibrosis
    Funding
    GAIN Act
    NACFC
    NCBIO
    News Article
    Nitric Oxide
    NTM Animal Model
    Partnership
    Patent
    Pathogens
    Press Release
    QIDP Status
    SARS-CoV-2
    Superbugs
    Therapy
    Video

    RSS Feed

Picture

Address

​4222 Emperor Blvd. Suite 470
​Durham, NC 27703

Contact Us

info@vasttherapeutics.com

Sector

Biopharmaceutical

Industry

​Biotechnology

    Sign Up for Email Alerts

Submit
​Forward-Looking Statement | Privacy | Terms of Use | Site Map
​Copyright © 2021 Vast Therapeutics - All Rights Reserved
  • Home
  • About
    • Company Overview
    • Our Team
    • Scientific Advisory Board
    • Careers
  • Technology
    • Nitric Oxide
    • Need for Antibiotic Alternatives
    • Broad Spectrum Efficacy
  • Applications
    • Cystic Fibrosis
    • NTM Lung Disease
    • Other Targets
  • Media
  • Investors